000 03109cam a2200409 i 4500
001 200454468
999 _c200454468
_d72680
003 TR-AnTOB
005 20241115144700.0
006 m o d
007 cr cn aaaau
008 201124s2021 nju ob 001 0 eng
020 _a9781119612698
_q(hardback)
020 _z9781119612742
_q(e-book)
020 _z9781119612735
_q(epub)
040 _aDNLM/DLC
_beng
_erda
_cDLC
_dTR-AnTOB
041 0 _aeng
060 0 0 _aWH 380
_bB655 2021
096 _aWH380
_bB655 2021 EBK
245 0 0 _aBlood and marrow transplantation long term management :
_bsurvivorship after transplant /
_cedited by Bipin N Savani, André Tichelli.
250 _aSecond edition
264 1 _aNew Jersey :
_bWiley-Blackwell,
_c2021.
300 _a1 online resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
504 _aBIBINDX
520 _a"Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT and now HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients. The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long-term free of the disease for which they were transplanted. The changes over decades in the transplant recipient population and in the practice of HCT will have almost inevitably altered the composition of the long-term survivor population over time. Apart from an increasingly older transplant recipient cohort, the pattern of transplant indications has shifted from the 1990s when chronic myeloid leukemia made up a significant proportion of allo-HCT indications. Changes in cell source, donor types, conditioning regimens, GVHD prophylaxis, and supportive care have all occurred, with ongoing reductions in both relapse and non-relapse mortality (NRM) have been demonstrated"--
_cProvided by publisher.
650 2 _aHematopoietic Stem Cell Transplantation
_9143632
650 2 _aLong Term Adverse Effects
_xprevention & control
_9143633
650 2 _aDisease-Free Survival
_9143636
655 0 _aElectronic books
_2local
_92032
700 1 _aSavani, Bipin N.
_eeditor
_9143641
700 1 _aTichelli, André
_eeditor
_9143645
856 4 0 _uhttps://onlinelibrary.wiley.com/doi/book/10.1002/9781119612780
_zOnline access link to the resource
942 _2NLM
_cEBK